Clinical trials: Nonalcoholic Fatty Liver
NAFLD, TYPE 2 DIABETES
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.
- Conditions
- NAFLD, TYPE 2 DIABETES, METABOLIC SYNDROME
- Trial name
- NCT02216552
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD…
- Trial name
- NCT01030484
- Where
- 8 sites in United States
- Volunteers
- 2,501 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Non Alcoholic Fatty Liver Disease
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
The central hypothesis of this proposal is that a reduction in hepatic mitochondrial function is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis).
- Trial name
- NCT01327443
- Testing
- Weight loss, Exercise
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Missouri-Columbia
Liver Diseases
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis.
- Trial name
- NCT04454463
- Where
- 16 sites in United States
- Volunteers
- 1,649 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Gestational Diabetes Mellitus in Pregnancy
The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes
The thought is that Non-Alcoholic Fatty Liver Disease (NAFLD) plays a key role in the progression to prediabetes/T2DM in those with a history of Gestational Diabetes (GDM).
- Trial name
- NCT01855386
- Testing
- Subjects with Gestational Diabetes, Controls without Gestational Diabetes
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Florida
Non-Alcoholic Fatty Liver Disease
Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease
This study was designed to assess the effect of dapagliflozin on body weight, blood sugar, liver enzymes, and blood fats in adults with non-alcoholic fatty liver disease (NAFLD), a condition involving excess fat accumulation in…
- Trial name
- NCT07881796
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Pakistan
- Volunteers
- 146 people
- Sponsor
- Shalamar Hospital
Non-Alcoholic Fatty Liver Disease
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
the purpose of this clinical trial is to assess the efficacy and safety of Orotic Acid Carnitine Complex Capsules (Godex®) in comparison to a placebo control group in patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06152991
- Testing
- GODEX
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Yoon Jun Kim
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Study of ECC4703 With Sulfasalazine and Pitavastatin
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis.
- Trial name
- NCT07726368
- Testing
- ECC4703, Sulfasalazine, Pitavastatin
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Visceral Obesity, Non-alcoholic Fatty Liver
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their…
- Conditions
- Visceral Obesity, Non-alcoholic Fatty Liver, Postmenopausal
- Trial name
- FATHIS+ (NCT06377631)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- 2 sites in Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fatty Liver, Nonalcoholic
Efficacy and Safety of Fermented Ginseng Powder on Liver Function
This study was conducted to investigate the effects of daily supplementation of fermented ginseng powder on improvement of Liver function.
- Trial name
- NCT03260543
- Testing
- fermented ginseng powder
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Non Alcoholic Fatty Liver Disease, Type2 Diabetes Mellitus
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This D-LIFT (Effect of dulaglutide on Liver Fat) trial is an investigator initiated, prospective, open label, randomized clinical study to examine the effect of dulaglutide 0.75 mg subcutaneously weekly for 4 weeks, followed by…
- Trial name
- D-LIFT (NCT03590626)
- Testing
- Dulaglutide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Medanta, The Medicity, India
Fatty Liver Disease
A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
Aims: To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) in assessing the degree of hepatic steatosis in an obese population, with liver biopsy as reference standard.
- Trial name
- NCT06487325
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ma Zhe
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
De Novo Lipogenesis in Severity of NAFLD
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- NCT03683589
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Missouri-Columbia
Fatty Liver, Obesity
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.
- Conditions
- Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD
- Trial name
- NICOFIB (NCT06599918)
- Testing
- Nicotinamide
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Obesity, Morbid, NASH
The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis
Background: Ketosis after bariatric surgery is a metabolic process that occurs when the body breaks down fat for energy because of not getting enough carbohydrates.
- Conditions
- Obesity, Morbid, NASH, Ketosis, Keto Acidosis
- Trial name
- NCT06338969
- Testing
- Carbohydrate Restriction after a Gastric Bypass
- Where
- Kazakhstan
- Volunteers
- 150 people
- Sponsor
- The Society of Bariatric and Metabolic Surgeons of Kazakhstan
NASH - Nonalcoholic Steatohepatitis, NAS
Hepatic Energy Fluxes in NASH and NAS Patients
Diseases along the nonalcoholic fatty liver disease spectrum, which are tightly coupled to the obesity epidemic, are soon to become the commonest indication for liver transplantation in the United States.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss
- Trial name
- NCT03997422
- Testing
- Vertical Sleeve Gastrectomy (VSG)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
NASH - Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo.
- Trial name
- NCT03468556
- Testing
- SNP-610
- Volunteers
- 80 people
- Sponsor
- Sinew Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.